



2

SRI International

DTIC
ELECTE
JUN 24 1992
S A D

Quarterly Report No. 5 • June 1992

DEVELOPMENT OF A THERAPEUTIC AGENT FOR WOUND-HEALING ENHANCEMENT

Amrit K. Judd, Ph. D., Senior Peptide Chemist
Bio-Organic Chemistry Laboratory

SRI Project LSU-2323

Prepared for:

Naval Medical R&D Command
National Naval Medical Center
Combat Casualty Care, Research Area Manager
Building 1 (Tower Bldg.), 11th Floor
8901 Wisconsin Avenue
Bethesda, Maryland 20889-5044

Attn: Capt. Stephen B. Lewis, Scientific Officer

Contract No. N00014-91-C-0066

Approved:

Masato Tanabe, Ph.D.
Director
Bio-Organic Chemistry Laboratory

This document has been approved
for public release and sale; its
distribution is unlimited.

92-16231

92 6 18 018

SCIENTIFIC PROGRESS DURING THIS QUARTER

Peptide Synthesis

During this quarter we prepared four peptides, as listed below:

PDGF A (53-63)	Peptide #5, Table 3, p. 18 in the original proposal
PDGF A (66-78)	Peptide #6, Table 3, p. 18 in the original proposal
PDGF A (77-88)	Peptide #7, Table 3, p. 18 in the original proposal
PDGF B (25-42)	Peptide #2, Table 4, p. 18 in the original proposal

Biological Assays

During this quarter we conducted cell-binding experiments and assays for mitogenesis and chemotaxis on the four peptides mentioned above. The results are shown in Tables 1 through 3. None of these peptides showed any cell binding or mitogenesis. PDGF A (77-88) showed chemotaxis. We are repeating the assay for this peptide.

Table 1
RESULTS OF COMPETITIVE BINDING ASSAY

Peptide	Concentration (ng or µg per well)	CPM	Average ± SD	Maximum Binding	Inhibition (%)
¹²⁵ I PDGF	5 ng	37,890	36,674 ± 2,329	100	0
		33,988			
		38,143			
PDGF BB	50 ng	19,689	19,626 ± 1,542	54	46
		21,135			
		18,053			
	25 ng	22,427	22,609 ± 669	62	38
		22,049			
		23,350			
	12.5 ng	29,197	29,525 ± 286	81	19
		29,662			
		29,717			
	6.25 ng	32,486	34,044 ± 1,352	93	7
		34,744			
		34,903			

Accession For	
NTIS CRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By <i>per A242529</i>	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
<i>A-1</i>	



Table 1 (concluded)

PDGF A (53-63)	3.125 ng	35,150 37,819 37,923	36,964 ± 1,572	100	0
	1.56 ng	36,002 37,475 36,137	36,538 ± 814	100	0
	500 µg	31,288 31,691 32,193	31,724 ± 453	87	13
	250 µg	36,764 37,412 27,440	33,872 ± 5,580	83	17
	125 µg	37,063 37,758 38,405	37,742 ± 671	92	8
	500 µg	39,403 37,505 37,546	38,151 ± 1,084	93	7
	250 µg	39,071 41,365 39,426	39,954 ± 1,235	98	2
	125 µg	40,465 40,564	35,349 ±	91	9
	500 µg	40,071 37,691 38,879	38,880 ± 1,190	100	0
	250 µg	38,983 38,805 39,532	39,107 ± 379	100	0
	125 µg	38,631 38,176 37,584	38,131 ± 523	98	2
	500 µg	32,668 32,415 33,447	32,843 ± 538	80	20
PDGF B (25-42)	250 µg	29,453 31,978 31,483	30,972 ± 1,338	76	24
	125 µg	35,117 34,305 36,278	35,233 ± 992	86	14

Table 2
THYMIDINE INCORPORATION AT PEPTIDE CONCENTRATION ($\mu\text{g/ml}$)

<u>Peptide</u>	<u>Control (media)</u>	<u>1 0 0 0</u>	<u>5 0 0</u>	<u>2 5 0</u>
PDGF A (53-63)	1,607 $\pm$ 305	1,137 $\pm$ 73	1,427 $\pm$ 197	1,761 $\pm$ 118
PDGF A (66-78)	1,544 $\pm$ 174	1,613 $\pm$ 121	1,759 $\pm$ 208	1,532 $\pm$ 276
PDGF A (77-88)	1,474 $\pm$ 315	1,507 $\pm$ 143	1,630 $\pm$ 297	1,637 $\pm$ 147
PDGF B (25-42)	1,961 $\pm$ 144	2,664 $\pm$ 943	1,828 $\pm$ 218	1,902 $\pm$ 209
PDGF	100 ng	11,681 $\pm$ 911		
	10 ng	3,935 $\pm$ 336		
	1 ng	1,897 $\pm$ 271		
	Media	1,527 $\pm$ 282		

Table 3
CHEMOTACTIC ACTIVITY OF PEPTIDES

<u>Peptide</u>	<u>Concentration (mg or ng/ml)</u>	<u>OD₆₅₀^a</u>	<u>S D</u>	<u>Chemotactic Activity</u>
Media		0.015	0.002	—
PDGF A (53-63)	250 μg	0.011	0.002	—
PDGF A (66-78)	250 μg	0.023	0.025	—
PDGF A (77-88)	250 μg	0.053	0.010	+
PDGF B (25-42)	250 μg	0.006	0.006	—
PDGF	20 ng	0.030	0.014	+

^aPeptides were considered positive when the OD was 1-1/2 times more than that of the media.

PLANS FOR NEXT QUARTER

During the next quarter we plan to continue the synthesis of peptides and to conduct cell-binding, mitogenesis, and chemotaxis assays.